Corporate Corridor | Pharma has a tough climb to regain investor faith
Compliance-related issues with the US FDA just don’t seem to be going away any time soon. In India, a key threat is the government’s efforts to make drugs affordable, and what policy changes it adopts to fulfil that objective.
July 16, 2019 / 04:37 PM IST
Will FY20 be the year when the Indian generic pharmaceutical sector regains its lost glory? Yes, you want to say, when you read news that Dr Reddy’s Laboratories has won a case that allows it to keep selling a key drug in the US market. The US Federal Appeals Court ruled that Dr Reddy’s generic version of Indivior’s Suboxone did not infringe two patents.
The incremental financial implication of this ruling is not much because Dr Reddy’s is already selling...